Thermo Fisher Scientific Inc. · Healthcare
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Healthcare
Medical - Diagnostics & Research
125,000
1980-03-17
0.97
Insider Activity
SPERLING SCOTT M
director
89.78 SH @ $0.00
2026-03-28
Keith R. Alexandra
director
66.02 SH @ $0.00
2026-03-28
Lynch Karen S
director
66.02 SH @ $0.00
2026-03-28
JOHNSON JENNIFER M
director
66.02 SH @ $0.00
2026-03-28
WEISLER DION J
director
79.22 SH @ $0.00
2026-03-28
Shafer Michael D
officer: Executive Vice President
1,607 SH @ $499.40
2026-03-11
Meyer James
officer: Sr. Vice President & CFO
0 SH @ $0.00
2026-03-01
Meyer James
officer: Sr. Vice President & CFO
0 SH @ $0.00
2026-03-01

TMO teams up with PRECISE on a major proteomics study, expanding its role in large biobank projects and precision medicine initiatives.

The Iran conflict has given investors a reason to sell just about everything. The Dow is in correction territory.

On April 10, 2026, we delve into the DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently facing a challenging market environment with its s

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region's most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for applicat.

CCLA Investment Management cut its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 11.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 267,601 shares of the medical research company's stock after selling 33,437 shares during the quarter. Thermo Fisher

BIP Wealth LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,599 shares of the medical research company's stock, valued at approximately $926,000. Several other hedge funds and other